Table 1. Clinicopathological characteristics of prostate cancer patients from the 2 Canadian Prostate Cancer Biomarker Network cohorts.
| Parameter | Test-TMA | Validation-TMA |
|---|---|---|
| Number of patients | 250 | 1,262 |
| Age in years at diagnosis | 62 (9) | 62 (9) |
| Follow-up in months | 113 (62) | 120 (71) |
| Biochemical recurrence | 77 (31) | 434 (34) |
| Biochemical recurrence type | ||
| PSA > 0.2 ng/ml and rising | 54 (22) | 264 (21) |
| Failed RP | 16 (6) | 85 (7) |
| PSA followed by a decision of treatment | 7 (3) | 85 (7) |
| Bone metastases | 11 (4) | 54 (4) |
| Castrate resistant | 13 (5) | 61 (5) |
| Death | ||
| Prostate-cancer-specific | 4 (2) | 36 (3) |
| Other cause | 17 (7) | 119 (9) |
| Overall | 21 (8) | 155 (12) |
| RP Gleason score | ||
| ≤3+3 | 64 (26) | 392 (31) |
| 3+4 | 104 (42) | 499 (39) |
| 4+3 | 42 (17) | 188 (15) |
| ≥4+4 | 36 (14) | 175 (14) |
| Undetermined | 4 (2) | 8 (1) |
| Pathological staging of the primary tumor | ||
| pT2 | 171 (68) | 788 (62) |
| pT3 | 77 (31) | 453 (36) |
| pT4 | 2 (1) | 21 (2) |
| Margin positive (invasive carcinoma involvement) | 91 (36) | 418 (33) |
Data given as number (percent) or median (standard error).
PSA, prostate-specific antigen; RP, radical prostatectomy.